40 completed, 3 unknown, 2 active not recruiting, 2 recruiting. 12 Phase 2, 11 Phase 1, 9 Phase 3, 6 Phase 4, 5 Not applicable.
Follow Cytomegalovirus Infection: new trials by email Literature Review of Cytomegalovirus Infection trials Research Report on Cytomegalovirus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection, Hematopoietic Stem Cells Transplantation | Recruiting | MSD Italia S.r.l. | 230 | 2025-05-09 | 2026-04-06 | |
| Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections Letermovir, Valganciclovir, Letermovir placebo - Cytomegalovirus Infection | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 80 | 2024-08-14 | 2026-01-02 |
| A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 2 | Withdrawn | ModernaTX, Inc. | 2024-02-08 | 2024-03-15 | |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 2 | Active not recruiting | ModernaTX, Inc. | 84 | 2023-04-05 | 2026-08-10 |
| A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045) Letermovir - Cytomegalovirus Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 120 | 2023-03-24 | 2025-03-25 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 1 | Completed | ModernaTX, Inc. | 9 | 2021-11-08 | 2023-09-11 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 3 | Terminated | ModernaTX, Inc. | 7454 | 2021-10-26 | 2025-12-15 |
| A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection BCV - Adenovirus Infections, Cytomegalovirus Infection | Phase 2 | Completed | SymBio Pharmaceuticals | 53 | 2021-08-16 | 2026-08-11 |
| A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine mRNA-1647 - Cytomegalovirus Infection | Phase 2 | Completed | ModernaTX, Inc. | 135 | 2021-06-18 | 2026-02-02 |
| Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 2 | Completed | ModernaTX, Inc. | 315 | 2020-01-09 | 2026-05-05 |
| MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) Letermovir tablet, Letermovir IV - Cytomegalovirus Infection, Cytomegalovirus Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 22 | 2019-12-27 | 2024-08-21 |
| Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) Letermovir, Placebo - Cytomegalovirus Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 220 | 2019-06-21 | 2024-08-22 |
| Dried Blood Spot Testing of CMV Detection in HCT Recipients DBS Self-Collection Kit, Standard Control Strategy - Cytomegalovirus Infection | Not applicable | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 622 | 2019-05-03 | 2026-02-25 |
| Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults mRNA-1647, mRNA-1443, Placebo - Cytomegalovirus Infection | Phase 1 | Completed | ModernaTX, Inc. | 181 | 2017-11-13 | 2021-01-15 |
| Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation virus-specific T-Cells - Cytomegalovirus Infection, Adenovirus Infection | Phase 1 / Phase 2 | Withdrawn | St. Anna Kinderkrebsforschung | 2016-08-03 | 2019-05-09 | |
| Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV Low dose HB-101, Medium dose HB-101, High dose HB-101 - Cytomegalovirus Infection | Phase 1 | Completed | Hookipa Biotech GmbH | 54 | 2016-06-01 | 2018-04-03 |
| Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After Hematopoietic Stem Cells Transplant in CMV-Seropositive Recipients Cytomegalovirus Infection, HSCT | Unknown | Maimónides Biomedical Research Institute of Córdoba | 100 | 2016-01-01 | 2017-07-06 | |
| Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers MBX400, Placebo - Cytomegalovirus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2015-11-10 | 2017-12-26 |
| Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss Placebo, Valganciclovir - Cytomegalovirus Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 54 | 2015-02-24 | 2024-10-16 |
| Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients Cytomegalovirus Infection, GVHD | Completed | Lophius Biosciences GmbH | 175 | 2014-07-01 | 2018-08-08 |
Showing 20 of 51. Sign in to see all of them.
Cytomegalovirus Infections (51) · Virus Diseases (7) · DNA Virus Infections (6) · Adenoviridae Infections (3) · Multiple Acyl Coenzyme A Dehydrogenase Deficiency (3) · Burkitt Lymphoma (2) · Congenital Abnormalities (2) · Hearing Loss (2) · Herpes Simplex (2) · Hodgkin Disease (2) · Leukemia, Hairy Cell (2) · Leukemia, Large Granular Lymphocytic (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Acute (2)
Herpesviridae Infections (50) · Infections (50) · DNA Virus Infections (45) · Virus Diseases (44) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Pathological Conditions, Signs and Symptoms (5) · Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Amino Acid Metabolism, Inborn Errors (3) · Genetic Diseases, Inborn (3) · Metabolism, Inborn Errors (3) · Mitochondrial Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3)
Valganciclovir (10) · mRNA-1647 cytomegalovirus vaccine (7) · letermovir (4) · Everolimus (3) · Ganciclovir (3) · Mycophenolic Acid (3) · Antiviral Agents (1) · Flow Cytometry (1) · Foscarnet (1) · Immunotherapy, Adoptive (1) · Polymerase Chain Reaction (1) · Tacrolimus (1) · Therapeutics (1) · Valacyclovir (1) · brincidofovir (1)
ModernaTX, Inc. (7) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · City of Hope Medical Center (3) · Merck Sharp & Dohme LLC (3) · Assistance Publique - Hôpitaux de Paris (2) · Cell Medica Ltd (2) · University of California, San Francisco (2) · Assistance Publique Hopitaux De Marseille (1) · Astellas Pharma Global Development, Inc. (1) · Baylor College of Medicine (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Hookipa Biotech GmbH (1) · Hospital do Rim e Hipertensão (1) · Jazz Pharmaceuticals (1) · Karolinska Institutet (1)
United States (26) · France (6) · United Kingdom (6) · Italy (5) · Spain (5) · Germany (4) · Japan (3) · Belgium (2) · Canada (2) · Australia (1) · Austria (1) · Brazil (1) · China (1) · Estonia (1) · Finland (1)
Karl S Peggs (2) · Mark A Jacobson, MD (2) · Ryotaro Nakamura (2) · Atul Humar, MD (1) · Caridad A. Martinez, MD (1) · Cecilia Soderberg-Naucler, MD, PhD (1) · Daniel C Brennan, MD (1) · Daniel Wolff, Prof. Dr. med. (1) · Geert Leroux-Roels, MD PhD Prof (1) · Inti Peredo, MD (1) · John Zaia (1)
PMID 38700045, PMID 39807668, PMID 38190492, PMID 16780548, PMID 18285548, PMID 19738014, PMID 23196955, PMID 23236375, PMID 23687088, PMID 24066743, PMID 24693891, PMID 25738669, PMID 25988935, PMID 26853648, PMID 27851688, PMID 30407512, PMID 30562587, PMID 31285228, PMID 31879324, PMID 32286644, PMID 32726431, PMID 33988338, PMID 34725108, PMID 34990047, PMID 36102707, PMID 36464218, PMID 37899366, PMID 38142695, PMID 38309519, PMID 38324766, PMID 38478705, PMID 38526054, PMID 38615067
2023 (2), 2005 (1), 2018 (1), R01CA077544 (1)